E-submission
Search
- Page Path
- HOME > Search
Original Article
- GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
- Young Wha Koh, Jae-Ho Han, Seong Yong Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh
- J Pathol Transl Med. 2017;51(2):152-158. Published online February 21, 2017
- DOI: https://doi.org/10.4132/jptm.2016.11.03
- 8,829 View
- 232 Download
- 19 Web of Science
- 18 Crossref
-
Abstract
PDF - Background
Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or refractory classical Hodgkin’s lymphoma (cHL). The purpose of this study was to measure the expression of GLUT1 and assess its prognostic significance and potential relationships with PD-L1, programmed death ligand 2 (PD-L2), and programmed death-1 (PD-1) expressions in cHL. Methods: Diagnostic tissues from 125 patients with cHL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine were evaluated retrospectively via immunohistochemical analysis of GLUT1, PD-L1, PD-L2, and PD-1 expression. Results: The median follow-up time was 4.83 years (range, 0.08 to 17.33 years). GLUT1, PD-L1, PD-L2, and PD-1 were expressed in 44.8%, 63.2%, 9.6%, and 13.6% of the specimens, respectively. Positive correlations were found between GLUT1 and PD-L1 expression (p = .004) and between GLUT1 and PD-L2 expression (p = .031). GLUT1 expression in Hodgkin/Reed-Sternberg (HRS) cells was not associated with overall survival or event-free survival (EFS) in the entire cohort (p = .299 and p = .143, respectively). A subgroup analysis according to the Ann Arbor stage illustrated that GLUT1 expression in HRS cells was associated with better EFS in advanced-stage disease (p = .029). A multivariate analysis identified GLUT1 as a marginally significant prognostic factor for EFS (p = .068). Conclusions: This study suggests that GLUT1 expression is associated with better clinical outcomes in advanced-stage cHL and is significantly associated with PD-L1 and PD-L2 expressions. -
Citations
Citations to this article as recorded by
- Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
Yuyang Pang, Tingxun Lu, Zijun Y. Xu-Monette, Ken H. Young
International Journal of Molecular Sciences.2023; 24(6): 5493. CrossRef - Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
Kun Wang, Xiaoyong Dai, Albert Yu, Chunyan Feng, Kewei Liu, Laiqiang Huang
Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef - TIMP-1 Dependent Modulation of Metabolic Profiles Impacts Chemoresistance in NSCLC
Wei Xiao, Pankaj Ahluwalia, Lan Wang, John Howard, Ravindra Kolhe, Amyn M. Rojiani, Mumtaz V. Rojiani
Cells.2022; 11(19): 3036. CrossRef - Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma
Chen Liu, Lin Liu
Frontiers in Genetics.2022;[Epub] CrossRef - Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
Wei Mu, Lei Jiang, Yu Shi, Ilke Tunali, Jhanelle E Gray, Evangelia Katsoulakis, Jie Tian, Robert J Gillies, Matthew B Schabath
Journal for ImmunoTherapy of Cancer.2021; 9(6): e002118. CrossRef - Tumor immunity is related to 18F‐FDG uptake in thymic epithelial tumor
Hisao Imai, Kyoichi Kaira, Kosuke Hashimoto, Hiroyuki Nitanda, Ryo Taguchi, Akitoshi Yanagihara, Tetsuya Umesaki, Ou Yamaguchi, Atsuto Mouri, Tomonori Kawasaki, Masanori Yasuda, Kunihiko Kobayashi, Hirozo Sakaguchi, Ichiei Kuji, Hiroshi Kagamu
Cancer Medicine.2021; 10(18): 6317. CrossRef - Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo
Nanae Yatagai, Takumi Hasegawa, Rika Amano, Izumi Saito, Satomi Arimoto, Daisuke Takeda, Yasumasa Kakei, Masaya Akashi, Peter J. Oefner
BioMed Research International.2021; 2021: 1. CrossRef - Current Role of Functional Imaging in the Management of Lymphoma
Bruce D. Cheson, Michel Meignan
Current Oncology Reports.2021;[Epub] CrossRef - Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
Maria Togo, Takehiko Yokobori, Kimihiro Shimizu, Tadashi Handa, Kyoichi Kaira, Takaaki Sano, Mariko Tsukagoshi, Tetsuya Higuchi, Satoshi Yokoo, Ken Shirabe, Tetsunari Oyama
British Journal of Cancer.2020; 122(11): 1686. CrossRef - Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Junshang Ge, Bo Xiang, Xu Wu, Jian Ma, Ming Zhou, Xiaoling Li, Yong Li, Guiyuan Li, Wei Xiong, Can Guo, Zhaoyang Zeng
Molecular Cancer.2019;[Epub] CrossRef - Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer
Norimitsu Kasahara, Kyoichi Kaira, Koichi Yamaguchi, Hiroaki Masubuchi, Hiroaki Tsurumaki, Kenichiro Hara, Yasuhiko Koga, Reiko Sakurai, Tetsuya Higuchi, Tadashi Handa, Tetsunari Oyama, Takehiko Yokobori, Kimihiro Shimizu, Takayuki Asao, Takeshi Hisada
Lung Cancer.2019; 134: 180. CrossRef - MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance
Barbara Marengo, Ombretta Garbarino, Andrea Speciale, Lorenzo Monteleone, Nicola Traverso, Cinzia Domenicotti
Oxidative Medicine and Cellular Longevity.2019; 2019: 1. CrossRef - Sustain, Adapt, and Overcome—Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia
Orsolya Matolay, Gábor Méhes
Frontiers in Oncology.2019;[Epub] CrossRef - Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma
Norimitsu Kasahara, Kyoichi Kaira, Pinjie Bao, Tetsuya Higuchi, Yukiko Arisaka, Bilguun Erkhem-Ochir, Noriaki Sunaga, Yoichi Ohtaki, Toshiki Yajima, Takayuki Kosaka, Tetsunari Oyama, Takehiko Yokobori, Takayuki Asao, Masahiko Nishiyama, Yoshito Tsushima,
Lung Cancer.2018; 119: 71. CrossRef - High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
Xiaofang Guo, Juan Wang, Jietian Jin, Hao Chen, Zijun Zhen, Wenqi Jiang, Tongyu Lin, Huiqiang Huang, Zhongjun Xia, Xiaofei Sun
Translational Oncology.2018; 11(3): 779. CrossRef - Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
Margarita Kirienko, Martina Sollini, Arturo Chiti
Clinical and Translational Imaging.2018; 6(6): 417. CrossRef - New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017
J. Han van Krieken
Journal of Hematopathology.2017; 10(1): 25. CrossRef - Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior
David J. Pinato, James R. Black, Sebastian Trousil, Roberto E. Dina, Pritesh Trivedi, Francesco A. Mauri, Rohini Sharma
OncoImmunology.2017; 6(11): e1358332. CrossRef
- Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
First
Prev
